Published in Cancer Weekly, June 2nd, 2009
"To maximally inhibit EGFR and then downstream VEGF activity, this phase I study was initiated to determine the maximum tolerated dose (MTD) of erlotinib with Wxed-dose cetuximab, and then combine with bevacizumab in patients with advanced malignancies. Patients and methods Patients with advanced malignancies likely to express EGFR were treated with a full dose of cetuximab intravenous weekly,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.